Highlights Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:57 2025-12-05 am EST			5-day change	1st Jan Change
107.08 ^CHF	+0.19%		+2.49%	+20.72%

Dec. 05	Novartis raises guidance and target price after strong execution
Dec. 04	Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	MT

Highlights

Lupin Gets Tentative U.S. FDA Nod for Siponimod Tablets	Dec. 04	MT
Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026	Dec. 03	RE
Tiziana Life Sciences Plans to Spin Out Asset as Separate Company	Dec. 02	DJ
US FDA approves Otsuka's drug for a type of kidney disease	Nov. 25	RE
Swiss Market Index Closes Higher; Emmi, Novartis Shares Up	Nov. 25	MT
Global markets live: Amazon, Alphabet, Boeing, Novartis, Novo Nordisk…	Nov. 25
Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	Nov. 25	MT
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Tuesday Ahead of Delayed Data Releases	Nov. 25	MT
Novartis Gets FDA Approval for Spinal Muscular Atrophy Treatment; Shares Rise Premarket	Nov. 25	MT
Novartis to present phase III trial for ianalumab in ITP	Nov. 25	RE
Novartis' Spinal Muscular Atrophy Treatment Wins US FDA Approval	Nov. 24	MT
Novartis prices Itvisma at a wholesale acquisition cost of $2.59 million	Nov. 24	RE
US FDA approves Novartis' gene therapy for rare muscle disorder	Nov. 24	RE
Novartis receives FDA approval for Itvisma	Nov. 24	RE
Novartis Receives FDA Approval for Itvisma®?, the Only Gene Replacement Therapy for Children Two Years and Older, Teens, and Adults with Spinal Muscular Dystrophy	Nov. 24	CI
DKSH Management Ltd. Announces Executive Changes	Nov. 21	CI
Global markets live: Nvidia, Walmart, Google, Amgen, Target…	Nov. 20
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Nov. 20	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Jobs Data	Nov. 20	MT
Novartis Maintains Growth Targets, Lifts Peak Sales Outlook for Kisqali, Scemblix	Nov. 20	MT
Novartis Expects Key Drugs, Recent Deals to Buoy Sales Into 2030s -- Update	Nov. 20	DJ
Novartis Rolls Forward Mid-Term Sales Outlook to 2025-2030, Expects Over 5% to 6% Sales CAGR	Nov. 20	MT
European shares advance on Nvidia results lift; investors assess US jobs data	Nov. 20	RE
Novartis Expects Steady Sales Growth Through 2030	Nov. 20	DJ
Novartis Targets Up to 6% Annual Growth in Sales Through FY30	Nov. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Novartis raises guidance and target price after strong execution

December 05, 2025 at 11:23 am EST

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 05:56 am EST